DOUBLE BLIND TRIAL OF QUETIAPINE(SEROQUEL) IN ANOREXIA NERVOSA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 一些证据表明，5-羟色胺和多巴胺通路的紊乱有助于核心进食障碍的病理生理学。这项初步研究试图确定最有效的剂量和副作用概况以及安全性/耐受性。如果达到这些目标，可能需要一项更大规模的双盲、安慰剂对照试验，以证明主要和次要目标以及确定反应是否针对某一亚型。这项研究可能足以检测核心进食障碍症状的不同。 主要结果：首先，我们将寻求证明奎硫平在减少耶鲁-布朗-康奈尔饮食障碍量表(YBC-EDS)和饮食障碍清单-2上的核心饮食障碍症状方面优于安慰剂。 次要结果：我们将寻求证明奎硫平在治疗8周时在降低DSM-IV AN(限制或暴食通便类型)患者的焦虑(STAI)、抑郁(汉密尔顿DI)、强迫症(YBOCS)或体重增加(BMI)方面优于安慰剂。此外，我们将试图证明奎硫平在减少阳性和阴性症状量表(PANSS)上的阳性和阴性症状方面优于安慰剂。最后，我们将使用匹兹堡奎硫平药物管理评估和访谈来跟踪奎硫平的反应、过程和结果。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Several lines of evidence suggest that disturbances of 5-HT and DA pathways contribute to core eating disorder pathophysiology. This pilot study seeks to determine the most effective dose and side effect profile and safety/tolerability. If these objectives are met, a larger double-blind, placebo-controlled trial may be necessary to demonstrate the primary and secondary objectives as well as to determine whether response is specific to AN subtype. This study may be adequately powered to detect a difference in core eating disorder symptoms. Primary Outcomes: Primarily we will seek to show that Quetiapine is superior to placebo in terms of reducing core eating disorder symptoms on the Yale-Brown-Cornell Eating Disorder Scale (YBC-EDS) and the Eating Disorders Inventory-2. Secondary Outcomes: We will seek to show that Quetiapine is superior to placebo in reducing anxiety (STAI), depression (Hamilton DI), obsessionality (YBOCS), or weight gain (BMI) in patients with DSM-IV AN (either restricting or binge-eating purging types) when administered for 8 weeks. Additionally, we will seek to show that Quetiapine is superior to placebo at reducing positive and negative symptoms on the Positive and Negative Symptom Scale (PANSS). Finally, we will track Quetiapine response, course and outcome using both the Pittsburgh Quetiapine Medication Management Assessment and interview.